With its recent investment in Quanterix, French diagnostics firm BioMérieux has added that company's Single Molecule Array high-sensitivity immunoassay platform to its offerings and positioned itself to take advantage of not only its own internal research on the platform but outside test development work as well.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.